Amicus Therapeutics (NASDAQ:FOLD) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Monday, February 25th.
Other research analysts have also recently issued reports about the company. Citigroup began coverage on Amicus Therapeutics in a research note on Monday, October 29th. They set a “neutral” rating and a $12.00 price objective on the stock. Guggenheim started coverage on Amicus Therapeutics in a research note on Monday, December 17th. They issued a “buy” rating and a $18.00 target price on the stock. ValuEngine cut Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. Finally, Cantor Fitzgerald initiated coverage on shares of Amicus Therapeutics in a report on Tuesday, January 29th. They issued an “overweight” rating and a $20.00 price objective for the company. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.60.
Shares of FOLD stock traded down $0.56 during trading on Monday, hitting $13.26. The company’s stock had a trading volume of 2,540,963 shares, compared to its average volume of 3,304,516. The firm has a market cap of $3.09 billion, a PE ratio of -9.97 and a beta of 1.85. Amicus Therapeutics has a 52 week low of $8.27 and a 52 week high of $17.62. The company has a quick ratio of 6.30, a current ratio of 6.40 and a debt-to-equity ratio of 0.94.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.13). The business had revenue of $32.64 million during the quarter, compared to analysts’ expectations of $30.81 million. Amicus Therapeutics had a negative return on equity of 54.21% and a negative net margin of 382.48%. The company’s quarterly revenue was up 121.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.41) EPS. On average, research analysts expect that Amicus Therapeutics will post -1.1 earnings per share for the current year.
In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $13.60, for a total value of $272,000.00. Following the sale, the chief executive officer now owns 678,844 shares in the company, valued at approximately $9,232,278.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO John F. Crowley sold 103,500 shares of the company’s stock in a transaction dated Tuesday, January 15th. The shares were sold at an average price of $11.71, for a total transaction of $1,211,985.00. Following the sale, the chief executive officer now owns 771,581 shares in the company, valued at $9,035,213.51. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 302,769 shares of company stock worth $3,668,771. 2.90% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of FOLD. Perceptive Advisors LLC grew its stake in Amicus Therapeutics by 3.3% in the 3rd quarter. Perceptive Advisors LLC now owns 20,694,424 shares of the biopharmaceutical company’s stock worth $250,196,000 after acquiring an additional 670,000 shares in the last quarter. FMR LLC lifted its position in shares of Amicus Therapeutics by 33.3% in the 4th quarter. FMR LLC now owns 17,943,523 shares of the biopharmaceutical company’s stock worth $171,900,000 after purchasing an additional 4,479,743 shares during the period. Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,807,772 shares of the biopharmaceutical company’s stock worth $203,205,000 after purchasing an additional 541,308 shares during the period. Vanguard Group Inc lifted its position in shares of Amicus Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc now owns 16,807,772 shares of the biopharmaceutical company’s stock worth $203,205,000 after purchasing an additional 541,308 shares during the period. Finally, BlackRock Inc. lifted its position in shares of Amicus Therapeutics by 0.9% in the 4th quarter. BlackRock Inc. now owns 16,521,820 shares of the biopharmaceutical company’s stock worth $158,279,000 after purchasing an additional 147,484 shares during the period.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.